Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress
Press Release – Oslo, Norway, October 12, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has today unveiled the results of its Hexvix[®] (APL-1706) Phase III clinical trial in China. A presentation scheduled for today at the 43[rd] Congress of the Société Internationale d’Urologie (SIU), confirms that, in a Chinese population, Hexvix blue light cystoscopy (BLC[®]) outperformed white light cystoscopy (WLC) in the detection of bladder cancer, particularly in cases of carcinoma in situ (CIS), and exhibited good